ArticleHuman vaccines & immunotherapeutics2013
Persistence of antibodies in adolescents 18-24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine.
Article in Human vaccines & immunotherapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 82 citations in OpenAlex.
- Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2020Guideline
- Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2017Trial
- A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: A phase I clinical trial.The Journal of infection · 2015Trial
- Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2015Trial
- Review
- Beyond Vaccination: Persistent Meningococcal Risk in Anti-C5-Treated aHUS-Case Report and Review of Literature.Journal of clinical medicine · 2026Article
- Potential public health impacts of gonorrhea vaccination programmes under declining incidences: A modeling study.PLoS medicine · 2025Article
- Modeling the persistence of 4CMenB vaccine protection against real world meningococcal B disease in adolescents.NPJ vaccines · 2024Article
- The potential public health impact of adolescent 4CMenB vaccination on Neisseria gonorrhoeae infection in England: a modelling study.BMC public health · 2023Article
- Postmarketing surveillance of adverse events following meningococcal B vaccination: data from Apulia Region, 2014-19.Human vaccines & immunotherapeutics · 2022Article
- Effectiveness of a serogroup B outer membrane vesicle meningococcal vaccine against gonorrhoea: a retrospective observational study.The Lancet. Infectious diseases · 2022Observational
- TIPICO X: report of the 10th interactive infectious disease workshop on infectious diseases and vaccines.Human vaccines & immunotherapeutics · 2021Article
- Genomic Characterization of Invasive Meningococcal Serogroup B Isolates and Estimation of 4CMenB Vaccine Coverage in Finland.mSphere · 2020Article
- Safety and tolerability of Meningococcus B vaccine in patients with chronical medical conditions (CMC).Italian journal of pediatrics · 2019Article
- Persistence of the immune response after 4CMenB vaccination, and the response to an additional booster dose in infants, children, adolescents, and young adults.Human vaccines & immunotherapeutics · 2019Review
- Adoption of Serogroup B Meningococcal Vaccine Recommendations.Pediatrics · 2018Article
- Global epidemiology of serogroup B meningococcal disease and opportunities for prevention with novel recombinant protein vaccines.Human vaccines & immunotherapeutics · 2018Review
- Spontanuous Demand For Meningococcal B Vaccination: Effects On Appropriateness And Timing.Human vaccines & immunotherapeutics · 2018Article
- Serum Bactericidal Antibody Responses of Students Immunized With a Meningococcal Serogroup B Vaccine in Response to an Outbreak on a University Campus.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2017Article
- Breadth and Duration of Meningococcal Serum Bactericidal Activity in Health Care Workers and Microbiologists Immunized with the MenB-FHbp Vaccine.Clinical and vaccine immunology : CVI · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We previously demonstrated the immunogenicity and tolerability of the serogroup B meningococcal vaccine, 4CMenB (Bexsero), in 11-17 y-olds randomized to receive 1, 2, or 3 doses at 1, 2, or 6 mo intervals. Participants in this extension study provided an additional blood sample 18-24 mo after last vaccine dose, to assess persistence of serum bactericidal activity with human complement (hSBA), and to compare with age-matched 4CMenB-naïve controls. In the original study, one month after one 4CMenB dose, 93% of subjects had seroprotective hSBA titers (≥4) against indicator serogroup B strains for individual vaccine antigens (fHbp, NadA and NZOMV), increasing to ~100% after two or three doses. After 18-24 mo, 62-73% of subjects given one dose had titers ≥4 against the three antigens, significantly lower rates than after two (77-94%) or three (86-97%) doses. Only proportions with titers ≥ 4 against NZOMV were significantly different between the two (77%) and three (90%, p < 0.0001) dose groups. These results confirm that two doses of 4CMenB, administered 1 to 6 mo apart, provide good levels of bactericidal activity against serogroup B meningococci, which were sustained at least 18-24 mo in over 64% of adolescents for all three tested vaccine-related antigens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.